Ironwood Pharmaceuticals (IRWD) Income from Non-Controlling Interests (2010 - 2023)
Ironwood Pharmaceuticals (IRWD) reported Income from Non-Controlling Interests of -$658000.0 for Q4 2023, up 52.01% sequentially from -$1.4 million in Q3 2023.
Ironwood Pharmaceuticals (IRWD) Income from Non-Controlling Interests (2010 - 2023) Analysis & Trends
Ironwood Pharmaceuticals (IRWD) has 2 years of Income from Non-Controlling Interests data on file, last reported at -$658000.0 in Q4 2023.
- For the quarter ending Q4 2023, Income from Non-Controlling Interests changed N/A year-over-year to -$658000.0; the trailing twelve-month figure through Dec 2023 stood at -$29.3 million (changed N/A YoY), and the FY2023 full-year result was -$29.3 million, changed N/A from the prior year.
- Income from Non-Controlling Interests climbed to -$658000.0 in Q4 2023, from -$1.4 million in the prior quarter.
- In the past five years, Income from Non-Controlling Interests ranged from a high of -$658000.0 in Q4 2023 to a low of -$27.3 million in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.86 Bn | 88.00 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.98 Bn | 32.24 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.48 Bn | 30.54 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.56 Bn | 23.49 Bn | 4.39 Bn | 395,346.10 |
| 5 | United Therapeutics | 23.01 Bn | 20.86 Bn | 648.10 Mn | - |
| 6 | RedHill Biopharma | 22.02 Bn | 22.02 Bn | - | - |
| 7 | Viatris | 20.40 Bn | 18.59 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.77 Bn | 16.46 Bn | 800.70 Mn | -12.70 Mn |
| 9 | Elanco Animal Health | 12.74 Bn | 12.31 Bn | 785.00 Mn | - |
| 10 | Ironwood Pharmaceuticals | 646.45 Mn | 425.98 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -658,000.00 |
| Sep 30, 2023 | -1.37 Mn |
| Jun 30, 2023 | -27.29 Mn |
| Sep 30, 2010 | 1.52 Mn |
| Jun 30, 2010 | -73,000.00 |